Low-dose adjuvant interferon for stage III malignant melanoma

Area of Science:

• Oncology
• Immunology

Background:

• The efficacy of interferon (IFN) as adjuvant therapy for stage III melanoma is debated, with conflicting results from previous studies.
• Adjuvant treatment strategies for melanoma aim to reduce recurrence and improve survival rates.

Purpose of the Study:

• To evaluate the effectiveness of low-dose interferon alpha2-b (IFN) as adjuvant therapy in stage III melanoma patients.
• To analyze survival outcomes in patients treated with or without adjuvant IFN.

Main Methods:

• Retrospective analysis of 60 stage III melanoma cases treated at a single institution between 1983 and 1998.
• Patients underwent lymphadenectomy, and a subset received low-dose IFN (3 MU TIW for 1 month, then 6 MU TIW for 11 months).
• Comparison of survival and disease-free survival between IFN-treated and observation groups.

Main Results:

• The IFN group (N=25) had a median survival of 7.9 years (5-year survival 69%), compared to 6.5 years (5-year survival 52%) in the observation group (N=35).
• No significant difference in overall survival was observed between the groups (P=0.91).
• Median disease-free survival was shorter in the IFN-treated group (1.4 years) versus the observation group (2.4 years), though not statistically significant (P=0.19).

Conclusions:

• Low-dose adjuvant interferon alpha2-b therapy did not demonstrate a significant survival advantage for stage III melanoma patients in this study.
• While toxicity was mild, the findings suggest that this regimen should not be routinely used outside of clinical trials.
• Further clarification is anticipated from upcoming cooperative group trials on the role of adjuvant IFN in melanoma treatment.